Diabetes drug cleared for European market

The Danish pharmaceutical company Novo Nordisk have won European approval for their diabetes drug Victoza. The European Commission approved the drug for marketing across the European Union. The European Medicines Agency had already offered a positive opinion.
Novo Nordisk praised the decision as a milestone, reportedly commented: “The European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults.”
The company will launch the drug throughout Britai, Denmark and Germany this summer. Victoza has previously been the subject of concerns over safety profile, with the Food and Drug Administration returning a split vote for approval in the US market.